Janus Henderson Global Life Sciences Fund - I Shares (JFNIX)

The fund primarily aims to achieve its investment objectives by allocating a minimum of 80% of its net capital (which may include funds borrowed for investment purposes) to securities of companies that its portfolio manager identifies as having a strong orientation towards life sciences. Additionally, as a core principle, the fund generally pledges to invest at least 25% of its overall assets in businesses specifically categorized within the "life sciences" sector.

JFNIX Mutual Fund Chart & Stats

$96.56

At close: Nov 11 4:00 PM EST

Previous Close: $96.56
Sub-Category: Global,International
Total Liabilities: $11.19M
Last Dividend Ex-Date: Dec 05, 2025
Expense Ratio: 0.78%
Holding Count: 84
Brand: Janus Investment Fund
Dividend Yield: (3.84%)
Category: Equity
Total Assets: 5.82B
Shares Outstanding: N/A
52-Week Range: $75.57 - $96.56

JFNIX Mutual Fund News

Novartis Files Documents Tied to Four-Series Notes Issuance

Novartis ( ($NVS) ) has shared an update. On November 9, 2026, Novartis Capital Corporation proposed, subject to stated terms and conditions, issuing and selling four series of notes: $500

36m ago6K NVS

Novartis says long-term Rhapsido data show sustained efficacy

Novartis (NVS) announced 52-week results from the Phase III RemIND program evaluating Rhapsido in chronic inducible urticaria. In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily

5h agoNVS NOT

Midday Fly By: Nvidia CEO resigns, Hancock Whitney acquires Trustmark

The major averages were higher near noon despite Nvidia’s CEO resignation putting pressure on technology shares. The Nvidia turmoil comes just one session after the semiconductor sector helped lead a

5h agoAMD GIS

Eli Lilly Stock (LLY) Jumps as China Approves Its Weight-Loss Pill

China is a huge market with 1.4 billion people.

6h agoLLY NVO

AbbVie Crohn’s Disease Study Update Offers Limited Near-Term Stock Impact

Abbvie ($ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie’s official study, “A Post-marketing Non-interventional Study for Upadacitinib in Patients With Moderately to Severely Active Crohn’s Disease

6h agoABBV

JFNIX Mutual Fund Smart Score

Neutral

Analyst Consensus

Strong BuyAverage Price Target: $118.93 (23.17% Upside)

Learn more about TipRanks Smart Score

Top 10 Holdings

The fund's ten largest positions
Name	Weight %
LLYEli Lilly And Company	9.41%
JNJJohnson & Johnson	7.09%
ABBVAbbvie	4.67%
UNHUnitedhealth Group Inc.	4.54%
AZNAstraZeneca plc	3.93%
RVMDRevolution Medicines, Inc.	3.02%
ARGXArgenx	2.63%
NVSNovartis AG	2.56%
TMOThermo Fisher Scientific	2.33%
PRAXPraxis Precision Medicines, Inc.	2.19%
Total	42.37%

Go to Holdings >